Total Payments
$1,217
2023 Payments
$381.64
Companies
13
Transactions
55
Medicare Patients
586
Medicare Billing
$113,302
Payment Breakdown by Category
Food & Beverage$1,053 (86.6%)
Education$163.50 (13.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,053 | 52 | 86.6% |
| Education | $163.50 | 3 | 13.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ITI, Inc. | $303.13 | 11 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $180.04 | 4 | $0 (2023) |
| Alkermes, Inc. | $160.37 | 5 | $0 (2023) |
| ABBVIE INC. | $133.09 | 7 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $115.79 | 10 | $0 (2022) |
| Lundbeck LLC | $72.69 | 4 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $60.51 | 3 | $0 (2022) |
| Shire North American Group Inc | $57.82 | 3 | $0 (2018) |
| Neurocrine Biosciences, Inc. | $42.50 | 2 | $0 (2022) |
| Bausch Health US, LLC | $39.66 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $381.64 | 14 | Teva Pharmaceuticals USA, Inc. ($126.92) |
| 2022 | $403.24 | 19 | Alkermes, Inc. ($106.96) |
| 2021 | $250.32 | 8 | ITI, Inc. ($211.19) |
| 2018 | $140.91 | 10 | Sunovion Pharmaceuticals Inc. ($83.09) |
| 2017 | $40.49 | 4 | Sunovion Pharmaceuticals Inc. ($16.22) |
All Payment Transactions
55 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/12/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.35 | General |
| Category: NEUROSCIENCE | ||||||
| 07/05/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $29.14 | General |
| Category: CNS | ||||||
| 06/28/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: NEUROSCIENCE | ||||||
| 05/03/2023 | Teva Pharmaceuticals USA, Inc. | — | Education | In-kind items and services | $111.45 | General |
| 04/19/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: CNS | ||||||
| 04/04/2023 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $19.37 | General |
| Category: PSYCHIATRY | ||||||
| 03/29/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: NEUROSCIENCE | ||||||
| 03/27/2023 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: Central Nervous System | ||||||
| 03/23/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: PSYCHIATRY | ||||||
| 02/28/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: PSYCHIATRY | ||||||
| 02/14/2023 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: Immunology | ||||||
| 02/01/2023 | Bausch Health US, LLC | APLENZIN (Drug), WELLBUTRIN | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Neurology | ||||||
| 01/30/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: NEUROSCIENCE | ||||||
| 01/09/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2022 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: Central Nervous System | ||||||
| 12/07/2022 | Bausch Health US, LLC | APLENZIN (Drug), WELLBUTRIN | Food and Beverage | In-kind items and services | $11.76 | General |
| Category: Neurology | ||||||
| 11/17/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Neuropsychiatry | ||||||
| 11/11/2022 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.31 | General |
| Category: PSYCHIATRY | ||||||
| 09/29/2022 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: PSYCHIATRY | ||||||
| 09/21/2022 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $78.76 | General |
| Category: CNS | ||||||
| 09/19/2022 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $25.62 | General |
| Category: Central Nervous System | ||||||
| 09/13/2022 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA INITIO | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: CNS | ||||||
| 09/13/2022 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA INITIO | Food and Beverage | In-kind items and services | $11.79 | General |
| Category: CNS | ||||||
| 08/29/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: NEUROSCIENCE | ||||||
| 08/22/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: Neuropsychiatry | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 130 | 384 | $37,174 | $21,259 |
| 2022 | 5 | 159 | 459 | $50,875 | $31,738 |
| 2021 | 5 | 126 | 345 | $46,385 | $31,123 |
| 2020 | 6 | 171 | 385 | $54,189 | $29,183 |
Total Patients
586
Total Services
1,573
Medicare Billing
$113,302
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 88 | $17,600 | $11,557 | 65.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 95 | $15,200 | $8,371 | 55.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 14 | 28 | $1,260 | $716.79 | 56.9% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 42 | 173 | $3,114 | $614.04 | 19.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 39 | 132 | $25,510 | $17,331 | 67.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 112 | $16,900 | $10,543 | 62.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 26 | 104 | $4,455 | $2,539 | 57.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 21 | $2,390 | $972.66 | 40.7% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2022 | 38 | 90 | $1,620 | $353.16 | 21.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 36 | 102 | $19,380 | $14,533 | 75.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 40 | 134 | $19,430 | $12,284 | 63.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 32 | $3,430 | $1,918 | 55.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 22 | 60 | $2,700 | $1,630 | 60.4% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 12 | 17 | $1,445 | $756.53 | 52.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 48 | 124 | $23,254 | $12,634 | 54.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 49 | 158 | $22,487 | $11,905 | 52.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 31 | 43 | $4,244 | $1,901 | 44.8% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 18 | 31 | $2,685 | $1,730 | 64.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 14 | 17 | $919.00 | $706.52 | 76.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 11 | 12 | $600.00 | $305.92 | 51.0% |
About Dr. Suzy Nashed, MD
Dr. Suzy Nashed, MD is a Psychiatry healthcare provider based in Elkton, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1629062492.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Suzy Nashed, MD has received a total of $1,217 in payments from pharmaceutical and medical device companies, with $381.64 received in 2023. These payments were reported across 55 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($1,053).
As a Medicare-enrolled provider, Nashed has provided services to 586 Medicare beneficiaries, totaling 1,573 services with total Medicare billing of $113,302. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry
- Location Elkton, MD
- Active Since 09/07/2005
- Last Updated 10/30/2023
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1629062492
Products in Payments
- CAPLYTA (Drug) $303.13
- VRAYLAR (Drug) $133.09
- LATUDA (Drug) $115.79
- ARISTADA (Drug) $81.61
- LYBALVI (Drug) $78.76
- REXULTI (Drug) $74.63
- AUSTEDO (Drug) $68.59
- INGREZZA (Drug) $42.50
- APLENZIN (Drug) $39.66
- ABILIFY MAINTENA (Drug) $39.10
- ORLADEYO (Drug) $26.73
- CINRYZE (Drug) $21.60
- FIRAZYR (Drug) $19.73
- BRINTELLIX (Drug) $19.47
- TAKHZYRO (Biological) $16.49
- EUCRISA (Drug) $12.64
- Dymista (Drug) $11.63
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.